EUVIMEDEUVIMED entdecken
Crossref

Functional Metabolic Pathways Of Diabetes Nephropathy: A Critical Review

Richa Shakya, Jeetendra Kumar Gupta, Avijit Mazumder

International Journal of Drug Delivery Technology · 30.05.2026 · 16 (37s)

DOI: 10.25258/ijddt.16.37s.78 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 30.05.2026. Verfasst von Richa Shakya und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People have both type 1 and type 2 diabetes are more likely to acquire DN because of interaction between environmental and inherited factors. Diabetic nephropathy (DN), which affects 20% to 30% of persons with diabetes, is the main cause of end-stage renal disease (ESRD). New therapies could hyperglycemia or other factors thought to encourage DN formation as a target. Diabetic nephropathy, the most common reason for kidney impairment among patients starting renal replacement treatment, affects 30% of individuals with type 1 and type 2 diabetes. A total of 10 likely biological processes and 19 pathways were connected to candidate SNPs in the ICSN Pathway study. The responses of nearly all types of kidney cells to elevated glucose levels are similar. The major cause of kidney disease is diabetes-related kidney disease, often known as diabetic nephropathy. The renin-angiotensin system has a role in the production of of ROS, or reactive oxygen species. It will be beneficial to conduct research on the metabolic pathways activated by frequent glucose fluctuations. The involvement paths will differ based on race and gender divisions. Translational study in humans will support future customised medicines to reduce TGF production in the kidney. Diabetes is the main cause of end-stage renal disease and is also known as diabetic nephropathy, or kidney damage brought on by high blood sugar levels. Reninangiotensin-aldosterone system (RAAS) inhibitors may provide less benefit for patients with non-hypertensive type 1 diabetes when used to prevent microalbuminuria.

Zitieren

APA

Shakya, R., Gupta, J. K., & Mazumder, A. (2026). Functional Metabolic Pathways Of Diabetes Nephropathy: A Critical Review. International Journal of Drug Delivery Technology, 16(37s). https://doi.org/10.25258/ijddt.16.37s.78

Vancouver

Shakya R, Gupta JK, Mazumder A. Functional Metabolic Pathways Of Diabetes Nephropathy: A Critical Review. International Journal of Drug Delivery Technology. 2026;16(37s). doi:10.25258/ijddt.16.37s.78

BibTeX
@article{Shakya2026,
  author = {Shakya, Richa and Gupta, Jeetendra Kumar and Mazumder, Avijit},
  title = {Functional Metabolic Pathways Of Diabetes Nephropathy: A Critical Review},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {37s},
  doi = {10.25258/ijddt.16.37s.78}
}
Kostenlos starten →